Approved Use in Small Cell Lung Cancer
Lurbinectedin (brand name Zepzelca) is a chemotherapy agent, not an immunotherapy drug itself. It received accelerated FDA approval in June 2020 for adults with metastatic small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy.[1] In this context, it is used as a monotherapy following immunotherapy, specifically after prior treatment with drugs like PD-1/PD-L1 inhibitors (e.g., atezolizumab or durvalumab).[1][2]
Role in Immunotherapy Sequencing
Clinical guidelines position lurbinectedin as a second-line option after first-line immunotherapy-platinum doublets, which are standard for extensive-stage SCLC. The pivotal PM14-501 trial (ORR 35%, median duration 5.3 months) enrolled patients who had received immunotherapy in at least 60% of cases, showing efficacy regardless of prior PD-1/PD-L1 exposure.[2][3] It does not combine directly with checkpoint inhibitors in approved regimens but fills a gap post-immunotherapy relapse.
Ongoing Research in Combinations
Trials explore lurbinectedin with immunotherapies:
- Phase II LAGOON study combines it with atezolizumab (PD-L1 inhibitor) in relapsed SCLC, reporting promising response rates.[4]
- IMforte trial pairs it with pembrolizumab (PD-1 inhibitor).[5]
These aim to overcome immunotherapy resistance via lurbinectedin's DNA repair inhibition, potentially enhancing immune cell infiltration.
Comparison to Pure Immunotherapies
Unlike PD-1/PD-L1 inhibitors (e.g., Keytruda, Tecentriq), which activate T-cells, lurbinectedin targets tumor transcription and microenvironment modulation indirectly supporting immune response. No direct head-to-head trials exist; it's positioned as post-immunotherapy salvage.[3]
Sources
[1]: FDA Approval Summary
[2]: Zepzelca Prescribing Information
[3]: Trigo et al., Lancet Oncology 2020
[4]: ASCO 2023 LAGOON Update
[5]: ClinicalTrials.gov IMforte